Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
Phase 4
Completed
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- Registration Number
- NCT01799356
- Lead Sponsor
- Istanbul Bakirkoy Maternity and Children Diseases Hospital
- Brief Summary
We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1303
Inclusion Criteria
- Women diagnosed uncomplicated PID
- Patients age are between 14 with 45
- Pelvic tenderness and vaginal discharge
Read More
Exclusion Criteria
- Urinary Tract Enfections
- Tubo-ovarian abscess and complicated PID
- Hıstory of antibiotics treatment
- Other pelvic pain causes
- Endometriosis
- Delivery,abortion and surgery within last months
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description moxifloxacin Group Moxifloxacin Treatment at uPID with moxifloxacin Ofloxacin Group Ofloxacin Treatment at uPID with Ofloxacin plus metronidazole Ofloxacin Group Metronidazole Treatment at uPID with Ofloxacin plus metronidazole
- Primary Outcome Measures
Name Time Method Clinically cure 21 Days
- Secondary Outcome Measures
Name Time Method Microbiological cure 21 Days
Trial Locations
- Locations (4)
T.C.S.B Mardin Women and Children Hospital
🇹🇷Mardin, Turkey
T.C.S.B. İstanbul Training Research Hospital
🇹🇷Samatya, Fatih, Turkey
T.C.S.B. Kanuni Sultan Suleyman Training Hospital
🇹🇷İstanbul, Kucukcekmece, Turkey
T.C.S.B. Şişli Etfal Training Research Hospital
🇹🇷Şişli, Turkey